David W. Meline - 11 May 2022 Form 3 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Financial Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
11 May 2022
Net transactions value
$0
Form type
3
Filing time
12 May 2022, 16:15:46 UTC
Previous filing
11 May 2022
Next filing
11 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MRNA Common Stock 2,583 11 May 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MRNA Stock Option (Right to Buy) 11 May 2022 Common Stock 26,020 $149.52 Direct F1
holding MRNA Restricted Stock Units 11 May 2022 Common Stock 6,415 $0.000000 Direct F2
holding MRNA Restricted Stock Units 11 May 2022 Common Stock 3,830 $0.000000 Direct F3
holding MRNA Stock Option (Right to Buy) 11 May 2022 Common Stock 25,618 $179.52 Direct F4
holding MRNA Stock Option (Right to Buy) 11 May 2022 Common Stock 271,303 $59.15 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F2 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F3 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F4 25% of this option vested and became exercisable on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F5 25% of this option vested and became exercisable on July 6, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Remarks:

The Reporting Person retired as Chief Financial Officer of the Issuer on May 9, 2022 but was reappointed as Chief Financial Officer of the Issuer on May 11, 2022 as reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on May 11, 2022.